Vito Amodio

TL;DR: Evidence is provided that cancer cells exploit adaptive mutability to evade therapeutic pressure to ensure their survival after drug exposure, and that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage.

TL;DR: The combinatorial targeting of EGFR and KRAS G12C is highly effective in CRC cells, patient-derived organoids and xenografts, suggesting a novel therapeutic strategy to treat KRASG12C CRC patients.

TL;DR: It is shown that a fully competent immune system is required to maximize the antiproliferative effect of VitC in breast, colorectal, melanoma, and pancreatic murine tumors, and this work provides a rationale for clinical trials combining ICT with high doses of Vit C.

TL;DR: These results indicate that CRCs carrying alterations in DNA repair pathways display dynamic neoantigen patterns that fluctuate over time, which could be relevant in the context of precision medicine.

TL;DR: In this article, the authors show that MMRd tumors respond to ICPis through CD4+ T-cell activation, and identify a unique role for CD4 + T cells in tumor rejection.